Sagimet Biosciences (NASDAQ:SGMT) Announces Quarterly Earnings Results

Sagimet Biosciences (NASDAQ:SGMT) issued its quarterly earnings data on Tuesday. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.01), FiscalAI reports.

Here are the key takeaways from Sagimet Biosciences’ conference call:

• Sagimet plans to initiate a Phase III denifanstat trial for moderate-to-severe acne within the next few months, enrolling approximately 800 patients, including 450 adolescents aged 12–17. Top-line results are expected shortly after last patient, last dose, anticipated around this time next year.
• The company highlighted Ascletis’ 480-patient Phase III trial in China, which reportedly delivered statistically significant improvements in investigator-assessed clear/almost-clear skin and inflammatory and non-inflammatory lesion counts, with about a 20-percentage-point placebo-adjusted improvement in the primary skin-clearance measure and no serious or Grade 3 adverse events.
• Management sees a substantial commercial opportunity in the estimated 10–15 million U.S. patients with moderate-to-severe acne, particularly those inadequately served by oral antibiotics and topicals. Early payer research suggested potential pricing above existing acne therapies, with management citing a preliminary floor of roughly $1,200–$1,500 per month, although no price has been set.
• Sagimet is developing additional FASN inhibitors, including a more potent oral candidate expected to enter Phase II by year-end and a topical formulation planned for first-in-human studies in early 2028. The company also acknowledged that denifanstat’s effects depend on continued treatment, with sebum and acne symptoms returning within roughly four to six weeks after discontinuation.

Sagimet Biosciences Price Performance

NASDAQ SGMT traded down $0.12 on Thursday, hitting $9.27. 345,455 shares of the stock were exchanged, compared to its average volume of 1,163,170. The company has a market capitalization of $301.98 million, a PE ratio of -7.26 and a beta of 3.37. The business’s fifty day moving average is $7.39 and its 200 day moving average is $6.52. Sagimet Biosciences has a 52 week low of $4.50 and a 52 week high of $10.01.

More Sagimet Biosciences News

Here are the key news stories impacting Sagimet Biosciences this week:

• Positive Sentiment: FDA clears Phase 3 acne trial: The randomized, placebo-controlled study is expected to begin in the second half of 2026 and enroll approximately 800 patients aged 12 and older, including about 450 adolescents. Denifanstat will be tested as a once-daily oral treatment, with efficacy measured through global assessment scores and inflammatory and non-inflammatory lesion counts. The clearance is a major step toward potentially expanding Sagimet’s commercial opportunity. FDA Phase 3 trial announcement
• Positive Sentiment: Analyst optimism: Canaccord Genuity raised its price target from $49 to $56 and maintained a “buy” rating. Wedbush also said Sagimet is making good progress toward bringing denifanstat to U.S. patients. These views indicate that analysts see meaningful value in the company’s clinical execution and pipeline. Canaccord price target report Wedbush commentary
• Neutral Sentiment: Clinical risk remains: The FDA authorization permits the study to proceed; it does not establish that denifanstat is effective or safe for approval. Sagimet is relying partly on prior results from license partner Ascletis in China, and the U.S. Phase 3 outcome remains the key future catalyst.
• Negative Sentiment: Continued losses and insider selling: Sagimet reported a quarterly loss of $0.26 per share versus an expected loss of $0.25, while HC Wainwright lowered its Q4 2026 loss estimate to $0.32 per share from $0.30. Director George Kemble also sold 20,206 shares for approximately $201,050, reducing his holdings by 24.5%. These factors may temper enthusiasm, although the regulatory news is the stronger immediate driver.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on SGMT shares. Canaccord Genuity Group upped their price target on Sagimet Biosciences from $49.00 to $56.00 and gave the stock a “buy” rating in a report on Wednesday. Citizens Jmp decreased their price objective on Sagimet Biosciences from $35.00 to $12.00 and set a “market outperform” rating on the stock in a report on Tuesday, May 19th. Oppenheimer reiterated an “outperform” rating on shares of Sagimet Biosciences in a research note on Friday, May 1st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sagimet Biosciences in a research note on Friday, July 17th. Finally, Guggenheim cut their price target on shares of Sagimet Biosciences from $27.00 to $25.00 and set a “buy” rating on the stock in a research report on Wednesday, April 29th. Seven analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $26.33.

Insider Activity

In other news, insider Elizabeth Rozek sold 10,545 shares of the company’s stock in a transaction dated Monday, July 20th. The shares were sold at an average price of $7.76, for a total value of $81,829.20. Following the sale, the insider directly owned 224,414 shares of the company’s stock, valued at approximately $1,741,452.64. This represents a 4.49% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO David Happel sold 64,051 shares of the firm’s stock in a transaction that occurred on Monday, July 20th. The shares were sold at an average price of $7.76, for a total value of $497,035.76. Following the completion of the sale, the chief executive officer directly owned 741,570 shares of the company’s stock, valued at approximately $5,754,583.20. The trade was a 7.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 113,646 shares of company stock valued at $920,491. 11.50% of the stock is owned by company insiders.

Institutional Trading of Sagimet Biosciences

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC boosted its stake in shares of Sagimet Biosciences by 0.6% in the 2nd quarter. Geode Capital Management LLC now owns 265,324 shares of the company’s stock valued at $2,023,000 after purchasing an additional 1,600 shares in the last quarter. Landscape Capital Management L.L.C. increased its holdings in shares of Sagimet Biosciences by 14.1% during the fourth quarter. Landscape Capital Management L.L.C. now owns 25,901 shares of the company’s stock worth $153,000 after buying an additional 3,198 shares in the last quarter. HighTower Advisors LLC increased its holdings in shares of Sagimet Biosciences by 10.1% during the fourth quarter. HighTower Advisors LLC now owns 37,189 shares of the company’s stock worth $220,000 after buying an additional 3,408 shares in the last quarter. American Century Companies Inc. boosted its holdings in shares of Sagimet Biosciences by 8.9% during the 2nd quarter. American Century Companies Inc. now owns 42,285 shares of the company’s stock valued at $322,000 after acquiring an additional 3,454 shares in the last quarter. Finally, Royal Bank of Canada grew its position in Sagimet Biosciences by 819.2% during the 4th quarter. Royal Bank of Canada now owns 4,927 shares of the company’s stock worth $29,000 after acquiring an additional 4,391 shares during the last quarter. Institutional investors own 87.86% of the company’s stock.

About Sagimet Biosciences

Sagimet Biosciences (NASDAQ: SGMT) is a clinical-stage biotechnology company focused on developing novel therapies for fibrotic diseases. The company’s lead program, CM-101, is a first-in-class fusion protein designed to neutralize the chemokine CCL24 and interrupt key drivers of tissue fibrosis. Preclinical data have demonstrated CM-101’s potential to block fibrotic signaling pathways in multiple organ systems, and the company has advanced the program into early-stage clinical evaluation for indications such as nonalcoholic steatohepatitis and systemic sclerosis.

In addition to CM-101, Sagimet maintains a pipeline of preclinical candidates targeting inflammation-driven fibrotic processes.